VR虚拟现实引导想象干预对改善肺癌手术患者焦虑的影响:一项随机对照试验

注册号:

Registration number:

ITMCTR2025001481

最近更新日期:

Date of Last Refreshed on:

2025-07-26

注册时间:

Date of Registration:

2025-07-26

注册号状态:

Registration Status:

补注册

Retrospective registration

注册题目:

VR虚拟现实引导想象干预对改善肺癌手术患者焦虑的影响:一项随机对照试验

Public title:

Effect of VR-Guided Imagery Intervention in Improving Anxiety among Lung Cancer Surgery Patients: A Randomized Controlled Trial

注册题目简写:

English Acronym:

研究课题的正式科学名称:

VR虚拟现实联合引导想象改善肺癌手术患者焦虑效果的研究

Scientific title:

Effect of VR-Guided Imagery in Improving Anxiety among Lung Cancer Surgery Patients

研究课题的正式科学名称简写:

Scientific title acronym:

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

李会琴

研究负责人:

李会琴

Applicant:

Li huiqin

Study leader:

Li huiqin

申请注册联系人电话:

Applicant telephone:

13832371967

研究负责人电话:

Study leader's telephone:

13832371967

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

1341618512@qq.com

研究负责人电子邮件:

Study leader's E-mail:

1341618512@qq.com

申请单位网址(自愿提供):

Study leader's website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website
(voluntary supply):

申请注册联系人通讯地址:

河北省石家庄市长安区健康路12号

研究负责人通讯地址:

河北省石家庄市长安区健康路12号

Applicant address:

No.12 Jiankang Road Chang 'an District Shijiazhuang Hebei Province China

Study leader's address:

No.12 Jiankang Road Chang 'an District Shijiazhuang Hebei Province China

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

河北医科大学第四医院

Applicant's institution:

The Fourth Hospital of Hebei Medical University

是否获伦理委员会批准:

Approved by ethic committee:

伦理委员会批件文号:

Approved No. of ethic committee:

2023KS193

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件

批准本研究的伦理委员会名称:

河北医科大学第四医院医学伦理委员会

Name of the ethic committee:

Medical Ethics Committee of the Fourth Hospital of Hebei Medical University

伦理委员会批准日期:

Date of approved by ethic committee:

2023/9/26 0:00:00

伦理委员会联系人:

刘海生

Contact Name of the ethic committee:

Liu haisheng

伦理委员会联系地址:

河北省石家庄市长安区健康路12号

Contact Address of the ethic committee:

No.12 Jiankang Road Chang 'an District Shijiazhuang Hebei Province China

伦理委员会联系人电话:

Contact phone of the ethic committee:

03118605794

伦理委员会联系人邮箱:

Contact email of the ethic committee:

office_hb4th@126.com

研究实施负责(组长)单位:

河北医科大学第四医院

Primary sponsor:

The Fourth Hospital of Hebei Medical University

研究实施负责(组长)单位地址:

河北省石家庄市长安区健康路12号

Primary sponsor's address:

No.12 Jiankang Road Chang 'an District Shijiazhuang Hebei Province China

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

河北

市(区县):

石家庄

Country:

China

Province:

Hebei

City:

Shijiazhuang

单位(医院):

河北医科大学第四医院

具体地址:

河北省石家庄市长安区健康路12号

Institution
hospital:

The Fourth Hospital of Hebei Medical University

Address:

No. 12 Jiankang Road Chang'an District Shijiazhuang City Hebei Province China

经费或物资来源:

自筹

Source(s) of funding:

Self-financing

研究疾病:

肺癌手术患者焦虑

研究疾病代码:

Target disease:

Anxiety in lung cancer surgery patients

Target disease code:

研究类型:

Study type:

干预性研究

Interventional study

研究设计:

Study design:

随机平行对照

randomized controlled trial(parallel group design)

研究所处阶段:

Study phase:

其它

Others

研究目的:

本研究旨在评估VR联合引导想象干预在降低接受选择性内镜手术的肺癌患者术前和术后焦虑方面的有效性,旨在为手术环境下的焦虑管理提供一种新的干预策略,并为临床实践和护理提供新的见解。

Objectives of Study:

This study aims to examine the effectiveness of VRGI intervention in reducing preoperative and postoperative anxiety among lung cancer patients undergoing elective endoscopic surgery aiming to provide a novel intervention strategy for anxiety management in surgical contexts and to contribute new insights into clinical practice and nursing.

药物成份或治疗方案详述:

Description for medicine or protocol of treatment in detail:

纳入标准:

1)择期行腔镜肺癌手术的患者、,18~80岁,2)ASA分级:I-II级,3)表达能力良好且自愿参加,4)无精神病史且其它严重疾患。

Inclusion criteria

1)Patients aged 18–80 years scheduled for elective thoracoscopic lung cancer surgery; 2)ASA grade: I–II; 3)Good communication skills and voluntary participation; 4)No history of mental illness or other serious diseases.

排除标准:

1)合并其它部位的癌症,2)合并心、脑、肺、肝脏、肾脏等器官疾病或者严重躯体疾病症,3)不愿配合实验者,4)正在接受或者过往参加过其它的心理干预者。

Exclusion criteria:

1)Concomitant malignancies in other body sites; 2) Combined heart, brain, lung, liver, kidney and other organ diseases or severe somatic diseases.; 3)Unwilling to cooperate with the experimenter; 4)Those who are currently receiving or have previously participated in other psychological interventions.

研究实施时间:

Study execute time:

From 2023-12-01

To      2024-03-31

征募观察对象时间:

Recruiting time:

From 2023-12-10

To      2024-03-25

干预措施:

Interventions:

组别:

干预组

样本量:

53

Group:

Intervention Group

Sample size:

干预措施:

VR联合引导想象

干预措施代码:

Intervention:

VRGI

Intervention code:

组别:

对照组

样本量:

53

Group:

Control group

Sample size:

干预措施:

常规护理

干预措施代码:

Intervention:

usual care

Intervention code:

样本总量 Total sample size : 106

研究实施地点:

Countries of recruitment
and research settings:

国家:

中国

省(直辖市):

河北

市(区县):

石家庄

Country:

China

Province:

Hebei

City:

shijiazhuang

单位(医院):

河北医科大学第四医院

单位级别:

三级甲等

Institution/hospital:

The Fourth Hospital of Hebei Medical University

Level of the institution:

Grade 3 Class A

测量指标:

Outcomes:

指标中文名:

状态特质焦虑量表得分

指标类型:

主要指标

Outcome:

State-trait anxiety inventory(STAI) score

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

心率

指标类型:

主要指标

Outcome:

heart rate

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

血压

指标类型:

次要指标

Outcome:

blood pressure

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

组织:

Sample Name:

none

Tissue:

人体标本去向

其它

说明

Fate of sample 

Others

Note:

征募研究对象情况:

结束

Completed

年龄范围:

最小 18
Min age years
最大 80
Max age years

Recruiting status:

Participant age:

性别:

Gender:

男女均可

Both

随机方法(请说明由何人用什么方法产生随机序列):

研究者运用计算机生成随机数字并产生随机分配结果。

Randomization Procedure (please state who generates the random number sequence and by what method):

The investigators use computer to generate random numbers and the random assignment results.

盲法:

Blinding:

是否共享原始数据:

IPD sharing:

Yes

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

http://www.medresman.org.cn/uc/index.aspx

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

http://www.medresman.org.cn/uc/index.aspx

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

病例记录表和EXCEL表格

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

Case record forms and Excel

数据管理委员会:

Data Managemen Committee:

Yes

研究计划书或研究结果报告发表信息
(杂志名称、期、卷、页,时间;或网址):

Publication information of the protocol/research results report
(name of the journal, volume, issue, pages, time; or website):

国际传统医学临床试验注册平台 京ICP备07032215号-5 提示:推荐使用IE8.0以上版本 宽屏显示分辨率下使用系统